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Abstract
Background: Management of the critically bleeding patient can be encountered in many medical and surgical
settings. Common for these patients is a high risk of dying from exsanguination secondary to developing
coagulopathy. The purpose of this meta-analysis was to systematically review and assess randomised controlled
trials (RCTs) performed on patients in acute need for blood transfusions due to bleeding to evaluate the effect of
viscoelastic haemostatic assay (VHA) guidance on bleeding, transfusion requirements and mortality.
Methods: PubMed and EMBASE were searched for RCTs that 1) randomised patients into receiving transfusions
based on either a VHA-guided (thromboelastography [TEG] or rotational thromboelastometry [ROTEM]) algorithm
(intervention group) or at the clinician’s discretion and/or based on conventional coagulation tests (control group)
and 2) adequately reported on the outcomes bleeding and/or transfusions and/or mortality. Data on bleeding,
transfusions and mortality were extracted from each trial and included in a meta-analysis.
Results: Fifteen RCTs (n = 1238 patients) were included. Nine trials referred to cardiothoracic patients, one to liver
transplantation, one to surgical excision of burn wounds and one to trauma. One trial was conducted with cirrhotic
patients, one with patients undergoing scoliosis surgery while one trial randomised treatment in post-partum
females presenting with bleeding. The amount of transfused red blood cells (RBCs), fresh frozen plasma (FFP) and
bleeding volume was found to be significantly reduced in the VHA-guided groups, whereas no significant
difference was found for platelet transfusion requirements or mortality.
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Background
Haemorrhage remains a major cause of potentially prevent-
able deaths worldwide. Trauma and massive transfusion is
associated with coagulopathy secondary to tissue injury, hy-
poperfusion, dilution and consumption of clotting factors
and platelets [1–9]. Patients undergoing cardiac surgery ac-
companied by cardiopulmonary bypass (CPB) stand a high
risk of dying due to microvascular bleeding and 11% have
excessive bleeding after CPB – in most cases found to be
nonsurgical [10, 11]. The non-surgical bleeding risk in these
patients originates in coagulopathy arisen from distortion
of the haemostatic system [12, 13]. Concepts of damage
control surgery in trauma have evolved, prioritizing early
control of the cause of bleeding by non-definitive means,
while haemostatic resuscitation seeks early control of coag-
ulopathy [14, 15]. Haemostatic resuscitation provides tr-
ansfusions with fresh frozen plasma (FFP) and platelets in
addition to red blood cells (RBCs) in an immediate and sus-
tained manner as part of the transfusion protocol for cr-
itically bleeding patients. Transfusion of RBCs, FFP and
platelets in a similar proportion as in whole blood prevents
both hypovolemia and coagulopathy [16, 17]. Although an
early and effective reversal of coagulopathy is documented
[16, 18], the most effective means of preventing
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coagulopathy of massive transfusion remains debated. Re-
sults from recent before-and-after studies in massively
bleeding patients and one randomised clinical trial (RCT)
indicate that trauma exsanguination protocols involving the
early administration of plasma and platelets are associated
with improved survival [19–22]. Furthermore, viscoelastic
haemostatic assays (VHAs), such as thrombelastography
(TEG)/rotational thromboelastometry (ROTEM), appear
advantageous for identifying coagulopathy in patients with
severe haemorrhage, as opposed to conventional coagula-
tion tests (CCTs) [23–25]. Current views recommend that
patients with uncontrolled bleeding, regardless of its cause,
should be treated with goal-directed haemostatic resuscita-
tion involving the early administration of plasma and plate-
lets and the use of VHAs should be considered. The aim of
goal-directed therapy should be to maintain a normal
haemostatic competence until surgical haemostasis is
achieved, as this appears to be associated with reduced
mortality [4, 6, 12, 20].
The aim of the present study was to perform a system-
atic review and meta-analysis of all published RCTs
comparing the effect of VHAs versus CCTs on blood
loss, transfusion requirements and mortality.
Materials and methods
An electronic search was conducted by one of the au-
thors (MF) in the PubMed and EMBASE database using
the following search strategy: (Thrombelastography OR
Thromb?elastograph* OR thromboelastograph OR
ROTEM OR TEG OR ROTEG OR Thromboelastometry
OR (algorithm AND bleeding)) AND ((randomized con-
trolled trial OR controlled clinical trial) OR (randomized
OR placebo OR trial)), to identify all RCTs done on
bleeding patients using treatment algorithms based on
results from either TEG or ROTEM. The search identi-
fied 1245 references in PubMed and 1835 references in
EMBASE. 222 duplicate findings were discarded, leaving
a total of 2858 references for further assessment. Refer-
ences were assessed by one of the authors (MF) and dis-
cussed and consensus reached with all authors in doubt
cases. Only published RCTs were eligible for this ana-
lysis. Inclusion criteria were 1) trial designs in which pa-
tients were randomly allocated to receive transfusions
based on either a VHA-guided (TEG or ROTEM) algo-
rithm (intervention group) or at the clinician’s discretion
and/or based on laboratory coagulation tests (control
group) and 2) references had to adequately report the
outcomes bleeding and/or transfusions and/or mortality.
Studies written in other languages than English were
also eligible for inclusion. Trials were excluded immedi-
ately based on title or abstract, if they did not meet the
inclusion criteria. Moreover, trials that were not per-
formed on humans and paediatric studies were also ex-
cluded. The remaining studies were evaluated and
assessed for relevance by all authors. Reference lists of
the included studies were searched for subsequent rele-
vant studies not identified by search engines. Correspond-
ing authors were contacted to retrieve inadequately
reported or missing data. Primary outcomes for data ex-
traction were all-cause mortality, total amount of bleeding
expressed either as bleeding at 12 h, 24 h or perioperative
amount of bleeding and amount of total RBC transfusions,
FFP transfusions and platelet transfusions. When amount
of blood transfusions was given in mL, calculations of the
corresponding number of units were done using the con-
version factors illustrated in table 1. The volume per unit
was an estimate of the standard volume of the given allo-
geneic blood product over the last years in the Capital Re-
gion Blood Bank, Rigshospitalet, Copenhagen. The latest
follow up data on mortality were used in the analysis of
all-cause mortality.
Statistics
Statistical meta-analyses were conducted using Review
Manager (RevMan) Version 5.3 (The Nordic Cochrane
Centre, The Cochrane Collaboration, 2014). Pooled esti-
mates and their 95% confidence intervals (CI) were cal-
culated using the inverse variance method. The random-
effects model was used in anticipation of significant het-
erogeneity [26]. Statistical heterogeneity was explored
using the inconsistency (I2) measure [27]. For all calcula-
tions, two-tailed P values of less than 0.05 were consid-
ered statistically significant.
Results
Study characteristics
We identified a total of 2858 references. All references
were screened by their title and abstract and 2812 refer-
ences were found not to be relevant for this meta-
analysis and were therefore excluded immediately, leav-
ing 46 references for further scrutiny (fig. 1). Another 31
references were excluded due to the reasons explained
in table 2. This left 15 RCTs with a total of n = 1238 pa-
tients to be included in this analysis. Of these trials, 9 re-
ferred to cardiothoracic patients [28–36] and one each
to liver transplantation [37], surgical excision of burn
wounds [38], trauma [22], cirrhotic patients [39], scoli-
osis surgery [40] and post-partum haemorrhage [41]. In
twelve studies the intervention group was guided by
TEG [22, 28, 29, 31–35, 37, 39–41] and in the remaining
three by ROTEM [30, 36, 38]. Seven trials applied both
results from CCTs and the discretion of the attending
Table 1 Conversion factors from mL to units
1U RBC 250 mL/U
1U FFP 270 mL/U
1U platelet concentrate 340 mL/U
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physician to guide the transfusions of the control group
[28, 31, 32, 35, 38, 40, 41], while the control groups of
eight trials were guided only by CCTs [22, 29, 30, 33, 34,
36, 37, 39] with the first transfused blood products being
guided solely at the clinician’s discretion before blood
analyses were available in two trials [22, 30]. Eleven trials
reported on bleeding [28–35, 37, 40, 41], nine reported
on mortality [22, 28, 30, 33, 34, 37, 39–41] and all stud-
ies reported on transfusion requirements. The transfu-
sion triggers for RBCs, FFP and platelet concentrates for
each study are demonstrated in table 3 and the individ-
ual study characteristics are presented in table 4.
Meta-analyses
All-cause mortality
Six trials were included in the meta-analysis of all-cause
mortality with a total of 579 patients of whom 291 pa-
tients were allocated to the intervention. Three trials con-
cerned patients undergoing cardiothoracic surgery [28, 30,
34] one trial concerned orthotopic liver transplantation
[37], one studied cirrhotic liver patients [39] and one stud-
ied trauma patients [22]. The meta-analysis demonstrated
no difference in survival between the groups with an OR
of 0.60 (95% CI 0.34 to 1.07; p = 0.08) (figure 2a).
Bleeding volume
Eleven RCTs reported on bleeding while only five of
these studies expressed perioperative, 24 or 12-h bleed-
ing as mean ± SD and were therefore eligible for meta-
analysis [28, 37, 40–42]. Comparison of the bleeding vol-
ume in 538 patients (305 in the intervention groups) re-
sulted in significantly reduced bleeding in the VHA
treated patients (standardized mean difference −1.40
[95% CI 2.57 to −0,23]; p = 0.02) (figure 2b).
Transfusion requirements
The analysis for transfusion requirements was limited to
six trials concerning RBC transfusions [22, 37, 38, 40–42]
Fig. 1 Process of inclusion of trials into meta-analysis
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and five trials were eligible for the meta-analysis on trans-
fusions of FFP and platelets, respectively [22, 37, 40–42].
All fifteen trials included in this analysis reported on
transfusions, while only the above mentioned described
the mean transfused amount per patient ± SD as required
for meta-analysis. Isolating RBC-transfusion requirements,
260 out of 453 patients were in the intervention group.
Random effects analysis resulted in a standardized mean
difference of −0.64 (95% CI −1.12 to −0.15; p = 0.01), being
statistically significant (figure 2c). Differences in FFP-
transfusions were calculated in 423 patients (246 in inter-
vention group) and resulted in a standardized mean differ-
ence of −1.98 (95% CI −3.41 to −0.54; p = 0.007), showing
a significant reduction in transfused FFP in the interven-
tion group (figure 2d). Numbers for transfused units of
platelets were available from the same 423 patients as with
FFP-transfusion requirements, however meta-analysis did
not reach statistical significance (standardized mean dif-
ference −0.34 [95% CI −0.92 to 0.24; p = 0.25]) (figure 2e).
Discussion
We found the total bleeding volume and the amount of
transfused RBCs and FFP to be significantly reduced in
the VHA-guided intervention groups compared to CCT-
guided control groups. Considering that most trials used
the same transfusion trigger for RBCs in both groups, the
difference in RBC requirements may be explained by a
better haemostatic competence in TEG/ROTEM-guided
groups accomplished through timely administration of
plasma and platelets, further supported by the reduction
of bleeding in the VHA-guided group of patients. In our
meta-analysis no statistically significant difference was
found between groups regarding all cause-mortality and
required amounts of platelets. The sizes of the respective
trial populations were small and a lack of cohesion in per-
mission of platelet inhibitors, anticoagulants, antifibrinoly-
tics and triggers used to guide resuscitation with blood
products was observed. The control groups were managed
either by clinical judgement combined with CCTs or by
the sole use of algorithms applying only CCT-triggers for
transfusion. The decision to transfuse potentially encom-
passes a bias to a greater number of transfusions between
clinicians with a different background and clinical prac-
tice, in alignment with Avidan et al. [29] finding a reduc-
tion in transfusions administered with CTT-algorithm
Table 2 Author and year, type of patients examined and reason
for exclusion in excluded scrutinized references
Reference (Author
and year)
Condition Reason for exclusion
Agarwal 2015 [46] Cardiac surgery Focus on platelet function
testing
Branco 2014 [47] Trauma Observational trial
Brilej 2016 [48] Trauma Observational trial
Capraro 2001 [49] Cardiac surgery No use of VHA
Despotis 1994 (a)
[50]
Cardiac surgery No use of VHA
Despotis 1994 (b)
[51]
Cardiac surgery No use of VHA
Dietrich 2008 [52] Cardiac surgery Focus on TXA-therapy
Einersen 2016 [53] Trauma Observational trial
Hajek 2010 [54] Cardiac surgery Intervention group is
managed both with
CCT and VHA-analyses
Hanke 2012 [55] Aortic surgery Not randomised – matched
control group
Harding 1997 [56] Liver transplantation Observational trial
Helm 1998 [57] Cardiac surgery Not randomised – matched
control group
Hoenicka 2015 [58] Cardiac surgery Focus on heparin
management
Hopkins 1983 [59] Acute
hypotension
General treatment algorithm
Israelian 2009 [60] Neuro surgery Possibly relevant. Manuscript
not available for reading.
Contact information of
corresponding author not
available.
Karkouti 2016 [61] Cardiac surgery Stepped-Wedge Clustered
RCT
Levin 2014 [62] Cardiac surgery Focus on protamine-
administration
Lier 2009 [63] Trauma Review
Mallaiah 2015 [64] Obstetric
haemorrhage
Before-after trial
Manikappa 2011 [65] Cardiac surgery Whole blood transfusions
Messenger 2011 [66] Trauma Prospective cohort study
Mishra 2015 [67] Cardiac surgery Focus on platelet function
testing
Naik 2015 [68] Major spinal
surgery
Non-randomised
Petricevic 2013 [69] Cardiac surgery Observational trial
Rahe-Meyer 2009 [70] Aortic surgery Non-randomised
Roullet 2015 [71] Orthotopic liver
transplantation
Non-randomised
Smart 2015 [72] Orthotopic liver
transplantation
Retrospective non-
randomised trial
Stancheva 2011 [73] Orthotopic liver
transplantation
Observational trial
Tarabarin 2013 [74] Bile duct surgery Possibly relevant. Manuscript
not available for reading.
Contact information of
corresponding author not
available.
Table 2 Author and year, type of patients examined and reason
for exclusion in excluded scrutinized references (Continued)
Weitzel 2012 [75] Cardiac surgery Focus on platelet function
Xu 2014 [76] Cardiac surgery Focus on platelet function
testing
VHA viscoelastic haemostatic assay, TXA tranexamic acid
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Table 3 Transfusion algorithm trigger values. Table explaining individual transfusion trigger values in the respective trials included in
the meta-analyses
Reference
(Author
and year)
RBC FFP Platelets Other
Control group Intervention
group
Control group Intervention
group
Control
group
Intervention group Control group Intervention
group
Shore-
Lesserson
1999 [33]
Hct < 25%
(during CPB
<21%)
Hct < 25%
(during CPB
<21%)
PT >150% of
control (2U FFP)
hTEG R >
20 mm (2U
FFP)
PC < 100 ·
103/μL (6U
PC)
PC < 100 · 103/μL
AND TEG MA <
45 mm (6U PC)
Fibrinogen
<100 mg/dL
10U of cryo
EACA 10 g if
failure
Fibrinogen
<100 mg/dL
10U of cryo
LY30 > 7.5%
EACA 10 g
Nuttall
2001 [31]
N/A N/A Clinician’s
discretion with
or without CCT
POC PT > 16.6 s
and/or POC
APTT > 57 s
Clinician’s
discretion
with or
without
CCT
PC < 102 · 103/mm3
and/or TEG MA
<48 mm (PC or
DDAVP)
Clinician’s
discretion
with or
without CCT
Fibrinogen
<144 mg/dL –
cryo
Royston
2001 [32]
N/A N/A Clinician’s
discretion with
or without CCT
R > 14 mm<
21 mm – 1 FFP
R > 21 mm<
28 mm – 2 FFP
R > 28 mm – 4
FFP
Clinician’s
discretion
with or
without
CCT
MA < 48 mm – 1
platelet pool
MA < 40 mm 2
platelet pools
Clinician’s
discretion
with or
without CCT
LY30 > 7.5% -
Aprotinin
Avidan
2004 [29]
Hb < 8 g/dL Hb < 8 g/dL If still bleeding
>100 mL/h after
aprotinin +
desmopressin
AND INR or
APTT ratio >
150% control –
4U FFP
Excessive
bleeding + R >
10 min – 4U
FFP
Persisting
excessive
bleeding
OR PC <
50x109/L –
1 platelet
pool
PFA-100® ADP
channel > 120 s,
epinephrine
channel > 170 s
treated with DDAVP
0.4 μg/kg – if
bleeding persisted
1 platelet pool
Bleeding
>100 mL/h
within 24 h
after surgery –
Aprotinin (2
Mu) +
desmopressin
(0.4 μg/kg)
LY30 > 7.5% +
bleeding
>100 mL/h –
aprotinin 2Mu
PFA-100® ADP
channel >
120 s,
epinephrine
channel >
170 s –
DDAVP
0.4 μg/kg
Ak 2009
[28]
Htc < 25%
(during CPB
<18%)
Htc < 25%
(during CPB
<18%)
PT > 14 s or
APTT > 150%
normal
R > 14 mm
<21 mm – 1
FFP
R≥ 21 mm
<28 mm – 2
FFP
R≥ 28 mm – 4
FFP
PC < 100 ·
103/μL
40≤MA < 48 mm –
1U platelets
MA < 40 mm 2U
platelets
Absence of
visible clots +
presence of
generalized
oozing-type
bleeding in
surgical field –
TXA
LY30 > 7.5% -
TXA
Westbrook
2009 [35]
Clinician’s
discretion with
CCT
Hb > 70 g/L Clinician’s
discretion with
CCT
11 min <
R(H)≤ 14 min –
1U FFP
14 min <
R(H)≤ 20 min –
2U FFP
200 min < R(H)
– 4U FFP
Clinician’s
discretion
with CCT
MA(H)≤ 41 mm –
5U platelets
TXA according
to clinician’s
discretion
with CCT
LY30 > 15% -
TXA
Girdauskas
2010 [30]
Htc < 25% (Hb
8.5 g/dL)
(during CPB
Htc < 20% (Hb
6.8 g/dL)) or
physiologic
transfusion
triggers
Htc < 25% (Hb
8.5 g/dL)
(during CPB
Htc < 20% (Hb
6.8 g/dL)) or
physiologic
transfusion
triggers
PT > 60s or INR
>1.5 – FFP
15 mL/kg body
mass
HEPTEM CT >
260 s – FFP
15 mL/kg body
mass
PC < 100 ·
103/μL – 1
platelet
concentrate
(A) HEPTEM MCF
35-45 mm – 1
platelet concentrate
(B) FIBTEM MCF
>8 mm and
HEPTEM MCF
<35 mm – 1
platelet concentrate
Fibrinogen
<1.2 mg/dL –
2 g fibrinogen
α2-
Antiplasmin
<80% - 3 g
TXA
FIBTEM
<8 mm – 2 g
fibrinogen
APTEM MCF/
HEPTEM MCF
>1.5 – 3 g
TXA
APTEM CT >
120 s –
3000 IU PPSB
Wang 2010
[37]
Hb <8 g/dL Hb <8 g/dL PT and aPTT >
150% control
R > 10 min PC <
50x109/L
MA < 55 mm – 6-
8U pooled platelets
Fibrinogen
<1 g/dL –
cryo
α-angle < 45° -
cryo
N/A N/A N/A N/A N/A N/A N/A N/A
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Table 3 Transfusion algorithm trigger values. Table explaining individual transfusion trigger values in the respective trials included in
the meta-analyses (Continued)
Paniagua
2011 [36]
Schaden
2012 [38]
Hb <8 g/dL Hb <8 g/dL Clinician’s
discretion with
or without CCT
EXTEM CT >
100 s – 4U FFP
Clinician’s
discretion
with or
without
CCT
EXTEM A10 <
45 mm and FIBTEM
>12 mm – 1U
platelets
concentrate
TXA and
fibrinogen
according to
clinician’s
discretion
with or
without CCT
EXTEM A10 <
45 mm and
FIBTEM A10 <
12 mm – 2 g
fibrinogen
Spindle
shaped trace
APTEM
A10> > EXTEM
A10 – 10 mg/
kg TXA
EXTEM LY30 >
10% - 10 mg/
kg TXA
Weber
2012 [34]
Hb <8 g/dL
(during CPB
Hb <6 g/dL)
or physiologic
transfusion
triggers
Hb <8 g/dL
(during CPB
Hb <6 g/dL)
or physiologic
transfusion
triggers
Transfused ≥4U
PRBCs without
new lab results
– 15 mL/kg FFP
INR > 1.4 or
aPTT > 50s – 20-
30 IU/kg pro-
thrombin com-
plex concen-
trate or 15 mL/
kg FFP
EXTEM CT > 80s
or HEPTEM
>240 s – 20-
30 IU/kg pro-
thrombin com-
plex concen-
trate or 15 mL/
kg FFP
PC <
80000/μL
EXTEM A10≤
40 mm and FIBTEM
A10 > 10 mm or
TRAP < 50 AU and/
or ASPI <30 AU
and/or ADP <
30 AU (second
choice)
Fibrinogen
pre-value <
200 mg/dL or
currently
<150 mg/dL –
25-50 mg/kg
fibrinogen
Suspected
platelet
dysfunction –
0.3 μg/kg
desmopressin
FIBTEM MCF =
0 mm –
25 mg/kg
fibrinogen
before
protamine
EXTEM A10≤
40 mm and
FIBTEM A10≤
10 mm – 25-
50 mg/kg
fibrinogen
TRAP < 50 AU
and/or ASPI
<30 AU and/
or ADP <
30 AU –
0.3 μg/kg
desmopressin
(first choice)
Barinov
2015 [41]
N/A N/A Clinician’s
discretion with
CCT
N/A Clinician’s
discretion
with CCT
N/A Clinician’s
discretion
with CCT
N/A
Gonzalez
2015 [22]
First units of
RBC
administered
according to
clinician’s
discretion only
Hb < 10 g/dL
First units of
RBC
administered
according to
clinician’s
discretion only
Hb < 10 g/dL
First units of
FFP
administered
according to
clinician’s
discretion only
INR≥ 1.5 – 2U
FFP
First units of
FFP
administered
according to
clinician’s
discretion only
ACT 111-139 s
– 2U FFP
ACT≥ 140 s –
2U FFP, 10-
pack cryo and
1U apheresis
platelets
ACT > 110 s –
2U FFP
PC < 100 ·
103/μL –
1U
apheresis
platelets
ACT≥ 140 s – 2U
FFP, 10-pack cryo
and 1U apheresis
platelets
MA < 55 mm – 1U
apheresis platelets
Fibrinogen
>150 mg/dL –
10-pack cryo
Suspicion on
fibrinolysis
with D-dimer
>0.5 μg/dL –
1 g TXA
ACT ≥ 140 s –
2U FFP, 10-
pack cryo and
1U apheresis
platelets
α-angle < 63° -
10-pack cryo
LY30≥ 7.5% -
1 g TXA (after
61% of
enrolment
LY30≥ 3% -
1 g TXA)
De Pietri
2015 [39]
Hb <8 g/dL Hb <8 g/dL INR > 1.8 –
10 mL/kg ideal
body weight
R > 40 min –
10 mL/kg ideal
body weight
PC < 50 ·
109/L – 1U
PLT
MA < 30 mm – 1U
apheresis platelets
Cao 2016
[40]
Hb < 70 g/L,
Htc < 25% - 2U
RBC
Hb < 70 g/L,
Htc < 25% - 2U
RBC
Clinican’s
discretion
R > 8 min – FFP
15 mL/kg
PC < 50 ·
109/L – 1U
PLT
MA < 70 mm – 1U
platelets
Fibrinogen <
0.0012 mg/L –
fibrinogen 2 g
α-angle < 72° -
fibrinogen 2 g
Control group = groups managed without the use of either TEG or ROTEM. Intervention group = groups managed with the use of TEG or ROTEM. Htc haematocrit,
Hb haemoglobin, PC platelet count, U units, PT prothrombin time, N/A not applicable, CCT conventional coagulation test, RBC red blood cell, FFP fresh frozen
plasma, PLT platelets, INR international normalized ratio, ACT activated clotting time, MA maximal amplitude, TXA tranexamic acid, R reaction time, aPTT activated
partial thromboplastin time, CPB cardiopulmonary bypass, hTEG heparinase-TEG, POC point of care
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Fig. 2 Forest plots a All-cause mortality b Perioperative, 24 h and 12 h bleeding c Total transfusion need – RBC d Total transfusion need – FFP e
Total transfusion need – Platelets
Fahrendorff et al. Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine  (2017) 25:39 Page 7 of 12
guided perioperative management versus transfusion guid-
ance based only on the physician’s discretion. Although
only a difference in amount of FFP and no statistical differ-
ence in the amount of platelets transfused between groups
was detected, the timing of these transfusions may differ
with VHA-analyses having shorter turn-around time than
conventional coagulation tests [43]. This accentuates the
importance of early administration of the appropriate blood
products as also emphasized by Cotton et al. [20] who
found reduced odds of mortality (74%) and transfusions in
a group of trauma patients managed with early and aggres-
sive resuscitation on admittance to the emergency depart-
ment. Although 24-h transfusion requirements were
reduced in patients treated according to the exsanguination
protocol, amounts of intraoperative transfusions were
found to be larger in this cohort in comparison with the
conventionally treated controls, illustrating the importance
of early resuscitation with blood products. Also Johansson
et al. [21] found similar results in patients undergoing sur-
gery for ruptured abdominal aortic aneurysm (rAAA) with
a proactive intraoperative administration of platelets and
FFP yielding an increase in survival in massively bleeding
rAAA patients. They found a significant reduction in post-
operative transfusions, indicating that early blood product
administration plays a pivotal role in improving haemosta-
sis in massive bleeders. Gonzalez et al. [22] have conducted
the first RCT to evaluate VHA-guided transfusion therapy
in trauma. They found a survival benefit in the TEG-guided
group especially with regards to less haemorrhagic and
early deaths. Additionally, they argued that the ad-
ministration of more platelets and FFP does not ne-
cessarily increase survival chances but highlight the
Table 4 Study characteristics Author and year, number of
patients allocated to control or intervention group and the type
of patients and/or procedures performed during the study
Reference
(Author and
year)
Control/
intervention
(n)
Type of patients/procedures
Shore-Lesserson
1999 [33]
52/53 Cardiac surgery
Moderate to high risk of microvascular
bleeding (single/multiple valve
replacement, combined CAB + valvular
procedure, cardiac reoperation, thoracic
aortic replacement). CPB performed
with moderate hypothermia.
Nuttall
2001 [31]
51/41 Cardiac surgery
All types of elective cardiac surgery
developing abnormal bleeding after
CPB.
Royston
2001 [32]
30/30 Cardiac surgery
10% in each group had heart
transplantation, 50% in each group had
revascularization (multiple grafts with
an estimated CPB-time >100 min), 40%
in each group Ross procedure, multiple
valve or valve and revascularization
surgery.
Avidan
2004 [29]
51/51 Cardiac surgery
Routine elective first time coronary
artery surgery with CPB. Cooled to 32 °
C.
Ak 2009 [28] 110/114 Cardiac surgery
Elective first time coronary artery
bypass graft (CABG) with CPB.
Westbrook
2009 [35]
37/32 Cardiac surgery
Presenting for cardiac surgery except
lung transplantations.
Girdauskas
2010 [30]
29/27 Aortic surgery
Patients undergoing aortic surgery with
hypothermic circulatory arrest. 25
patients with acute type A dissection.
Wang 2010 [37] 14/14 Orthotopic liver transplantation
Paniagua
2011 [36]
9/13 Cardiac surgery
Patients scheduled for cardiac surgery
with extracorporeal circulation with
major post-operative bleeding
(>300 mL).
Schaden
2012 [38]
16/14 Surgical excision of burn wounds
Surgical intervention performed on 3rd
day after trauma.
Weber
2012 [34]
50/50 Cardiac surgery
Patients scheduled for elective,
complex cardiothoracic surgery
(combined coronary artery bypass, graft
and valve surgery, double/triple valve
procedures, aortic surgery or redo
surgery) with CPB.
Barinov
2015 [41]
29/90 Postpartum obstetric haemorrhage
Gonzalez
2015 [22]
55/56 Trauma patients
Meeting criteria for massive transfusion
protocol (MTP) activation on arrival to
ED: systolic blood pressure <70 mmHg
or SBP 70 – 90 mmHg with heart rate
108 beats/min, in addition to any of
Table 4 Study characteristics Author and year, number of
patients allocated to control or intervention group and the type
of patients and/or procedures performed during the study
(Continued)
the following injury patterns:
penetrating torso wound, unstable
pelvic fracture, or abdominal ultrasound
suspicious of bleeding in more than
one region.
De Pietri 2015
[39]
30/30 Hepatic surgery
Patients with cirrhosis + significant
coagulopathy (defined as INR >1,8 and/
or platelet count <50 × 109/L)
undergoing invasive procedure.
Cao 2016 [40] 28/32 Scoliosis surgery
Patients with an expected surgical
bleeding > 1000 ml and the American
Society of Anesthesiologists rating I-II in
addition to a body mass index (BMI) 18
to 24 kg/m2
CAB coronary arterial bypass, CABG coronary artery bypass graft, CPB cardio
pulmonary bypass, MTP massive transfusion protocol, ED emergency
department, SBP systolic blood pressure, INR international normalised ratio
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effect of the appropriate treatment being given at the
optimal time rather than the amount of blood prod-
uct administered. Moreover, in patients undergoing
surgery with extracorporeal circulation, the use of
TEG/ROTEM heparinase analyses, where coagulopa-
thy can be identified despite patient being heparin-
ized, may provide an even earlier assessment of
coagulation status and thereby enable an earlier cor-
rection of coagulopathies, exemplified by Royston et
al. [32] and Girdauskas et al. [30].
Weber et al. [34] report a notably higher mortality
among their patients than usually seen in cardiac sur-
gery. Despite this, we did not find a significant difference
in mortality in the VHA-guided groups compared to
conventionally treated groups. However, our meta-
analysis suggested clinical difference in survival in pa-
tients having treatment based on VHA-results, in con-
gruence with a before- and after study conducted on
trauma patients by Johansson et al., showing a reduction
in mortality of approximately 30% in a group resusci-
tated using TEG results in patients requiring massive
transfusions [19]. Furthermore, a Cochrane review from
Wikkelsø et al. [44] found the use of TEG or ROTEM in
guiding resuscitation of bleeding patients to reduce all-
cause mortality and the number of patients transfused
with blood products, although no difference was found
with regard to excessive bleeding events and proportion
of massively transfused, in agreement with our results.
Also, NICE-report done by Whiting et al. [45] finds a
tendency to fewer transfusions of allogeneic blood prod-
ucts being administered in cardiac surgery patients
treated according to VHA-results when comparing to
patients managed with CCT-results, while no difference
was found with regard to trauma patients and post-
partum bleeding. The discrepancies in study selection
with the review from Whiting et al. [45] are explained in
table 5.
Limitations
A limited number of adequately reported trials were eli-
gible for our meta-analyses. Out of the 15 included trials
in this analysis, five did not report sufficient informa-
tion to be included in any of the meta-analyses
performed [29, 31, 32, 35, 36]. This meta-analysis has
an overweight of trials concerning cardio-thoracic pa-
tients, while other patient groups are only repre-
sented by a single RCT each, limiting comparability
of results. Furthermore, the studies included present
patients with bleeding originating from different aeti-
ologies. This can potentially be problematic in that
the severity of bleeding may vary.
Conclusions
In conclusion, the performed meta-analyses demon-
strated trends towards the superiority of treating haem-
orrhaging patients under the guidance of VHA-
algorithms. There is, however, a need for larger RCTs,
such as the ongoing trials “implementing Treatment Al-
gorithms for the Correction of Trauma Induced Coagu-
lopathy (iTACTIC)” NCT02593877.
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